Dengue vaccine candidate DengiAll enters Phase III trials in India with 10,000 volunteers enrolled Dengue affects nearly half the global population, causing 100–400 million infections yearly DengiAll aims to be a single-dose vaccine protecting against all four dengue virus serotypes
